Healthcare-associated infections

dgkh000605 10.3205/dgkh000605 urn:nbn:de:0183-dgkh0006054 Review Article Healthcare-associated infections Healthcare-assoziierte Infektionen Anand Anand Gargee G Dr. MD

All India Institute of Medical Sciences, Patna, Bihar, India, 801507, Phone: +91 9691180521All India Institute of Medical Sciences, Patna, Bihar, India

gargeea3@gmail.com author Lahariya Lahariya Rijhul R

All India Institute of Medical Sciences, Patna, Bihar, India

author German Medical Science GMS Publishing House

Düsseldorf

610 healthcare-associated infections antimicrobial resistance infection prevention and control antimicrobial stewardship healthcare-associated pathogens multidrug-resistant organisms Healthcare-assozzierte Infektionen antimikrobielle Resistenz Infektionsprävention und -kontrolle antibiotic Stewardship nosokomiale Krankheitserreger multiresistente Erreger 20251205 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). 2196-5226 20 GMS Hygiene and Infection Control GMS Hyg Infect Control 76 Hintergrund und Zielsetzung: Healthcare-assoziierte Infektionen (HAI) sind nach wie vor eine der Hauptursachen für Morbidität, Mortalität und erhöhte Gesundheitskosten weltweit. Trotz Fortschritten in der Infektionsprävention bleibt die Belastung durch HAI hoch, was durch die Zunahme antimikrobieller Resistenzen (AMR) und die zunehmende Komplexität der Patientenversorgung noch verschärft wird. Effektive Präventionsstrategien sind entscheidend für die Reduzierung der HAI-Raten und die Verbesserung der Heilungsergebnisse. Ziel des Reviews ist es, die klinische Bedeutung von HAI hervorzuheben, ihre Auswirkungen auf die Patientensicherheit zu analysieren und die Notwendigkeit robuster Surveillance- und IC-Programme im Gesundheitswesen zu unterstreichen.Ergebnisse: Die Studie ergab, dass weiterhin ein erheblicher Anteil der Krankenhauspatienten von HAI betroffen ist, wobei invasive Devices und multiresistente Erreger (MRE) die Hauptursachen sind. Die Surveillance kann in Kombination mit Protokollen zur gezielten Infektionskontrolle (IC) und mit kontinuierlicher Schulung des Personals die HAI-Inzidenz reduzieren und die Patientensicherheit verbessern. Darüber hinaus spielt der Einsatz antimikrobieller Stewardship-Programme und angemessener Hygienepraktiken zusammen mit neuen Technologien eine entscheidende Rolle bei der Eindämmung von MRE.Schlussfolgerung: Gesundheitssysteme müssen der HAI-Prävention Priorität einräumen, um die Patientensicherheit zu gewährleisten, Behandlungskosten zu senken und die wachsende Bedrohung durch AMR zu bekämpfen. Background and purpose: Healthcare-associated infections (HAIs) continue to be a leading cause of morbidity, mortality, and increased healthcare costs worldwide. Despite advances in infection prevention, the burden of HAIs remains high, exacerbated by the rise of antimicrobial resistance (AMR) and the growing complexity of patient care. Effective prevention strategies are critical to reducing HAI rates and improving patient outcomes. This review aims to highlight the clinical significance of HAIs, explore their impact on patient safety, and underscore the necessity for robust surveillance and infection control (IC) programs across healthcare settings.Results: The study found that HAIs continue to affect a significant proportion of hospitalized patients, with invasive devices and antimicrobial-resistant pathogens being key contributors. Surveillance systems, when combined with targeted IC protocols and continuous staff education, can reduce HAI incidence and improve patient safety. Moreover, the implementation of antimicrobial stewardship programs and proper hygiene practices along with emerging technologies plays a pivotal role in curbing the spread of resistant organisms.Conclusion: Healthcare systems must prioritize HAI prevention to safeguard patient safety, reduce treatment costs, and combat the growing threat of AMR. IntroductionThe Centers for Disease Control and Prevention (CDC) define a healthcare-associated infection (HAI) as one that occurs on or after the 3rd day of a patient’s hospital stay, with the admission day counting as day 1 . The CDC play a crucial role in addressing HAIs by providing national leadership in surveillance, outbreak investigations, laboratory research, and prevention efforts, with their National Healthcare Safety Network (NHSN) serving as the USA’s most widely used HAI tracking system and work toward eliminating these infections , . The World Health Organization (WHO) defines a HAI, also known as a nosocomial infection, as an infection occurring in a patient during their stay at a healthcare facility, starting on or after the 3rd day of admission, and can develop while receiving care or even after discharge . This makes HAIs a significant global concern, with the WHO highlighting their widespread occurrence in healthcare facilities worldwide, where they pose a constant health threat by prolonging hospital stays, escalating antimicrobial resistance (AMR), and placing significant financial burdens on health systems, patients, and their families, while causing preventable deaths , . The WHO emphasizes the urgent need to prevent and control HAIs, as they are major contributors to AMR, which disproportionately impacts low-resource settings, with up to 3.5 million deaths annually without immediate intervention . In the USA, HAIs account for approximately 2 million cases and 99,000 deaths annually, making them the fifth leading cause of death in acute-care hospitals, while in developing countries, HAI prevalence can soar to 30%–50% . The treatment of HAIs often requires broad-spectrum antibiotics, which increases the risk of multidrug-resistant organisms (MDRO), causing over a million deaths annually worldwide . In addition to the health impact, HAIs also impose a heavy financial burden on healthcare systems as well as on patients, diverting essential resources from other critical areas of patient care . Infected patients incur 2.8-fold higher costs and their hospital stays are 2.5-fold longer, adding an average of 11 extra days to their stay . The most critical HAIs are those linked to invasive devices, including central line-associated b</PlainText></TextGroup>loodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), ventilator-associated pneumonia (VAP), and surgical site infections (SSI) <TextLink reference="10"></TextLink>. Preventing and controlling HAIs is vital for improving patient outcomes and combating AMR. Strengthening infection control (IC) measures must be a priority in healthcare settings before resorting to antibiotics.</Pgraph></TextBlock> <TextBlock name="Global HAI prevalence and key pathogens responsible" linked="yes"> <MainHeadline>Global HAI prevalence and key pathogens responsible</MainHeadline><Pgraph>According to the WHO, HAIs are significantly more prevalent in low- and middle-income countries (LMICs) than in high-income countries <TextLink reference="4"></TextLink>. While HAIs are the most frequent adverse event in healthcare, the true global burden remains unclear due to difficulties in obtaining reliable data <TextLink reference="4"></TextLink>. The WHO divides the globe into six regions to streamline work and improve healthcare coordination. These regions are: African Region (AFR), Region of the Americas (AMR), South-East Asia Region (SEAR), European Region (EUR), Eastern Mediterranean Region (EMR), and Western Pacific Region (WPR) <TextLink reference="11"></TextLink>. HAIs caused by various pathogens, and their prevalence in specific infection types is summarized in Table 1 <ImgLink imgNo="1" imgType="table" /> <TextLink reference="12"></TextLink>. </Pgraph></TextBlock> <TextBlock name="Surveillance of HAI" linked="yes"> <MainHeadline>Surveillance of HAI</MainHeadline><Pgraph>HAI surveillance is very crucial for assessing their burden, identifying high-risk populations, and guiding infection prevention efforts. It relies on standardized case definitions, ensuring accurate data to effectively reduce HAI incidence and improve patient safety globally <TextLink reference="13"></TextLink>. The most widely used HAI surveillance criteria are those established by the CDC NHSN, the ECDC and the WHO <TextLink reference="14"></TextLink>, <TextLink reference="15"></TextLink>, <TextLink reference="16"></TextLink>. While all three organizations aim to monitor and reduce the burden of HAIs, use standardized criteria for HAI surveillance, and focus on identifying and reporting infections acquired in healthcare settings, they differ in scope and focus <TextLink reference="17"></TextLink>. The CDC NHSN focuses on specific infections in the U.S. with detailed reporting, the ECDC harmonizes surveillance across European countries, and the WHO provides a global framework for infection prevention and HAI surveillance with a broader approach to strengthening health systems <TextLink reference="17"></TextLink>.</Pgraph></TextBlock> <TextBlock name="Factors contributing to HAI" linked="yes"> <MainHeadline>Factors contributing to HAI</MainHeadline><SubHeadline>Invasive devices</SubHeadline><Pgraph>Invasive devices such as endotracheal tubes, urinary catheters, and central venous catheters are shown to be linked to higher rates of HAIs in ICU settings <TextLink reference="18"></TextLink>, <TextLink reference="19"></TextLink>. Invasive devices bypass the body’s natural defense and create entry points for infections, creating an easier pathway for microorganisms to enter and transfer between different parts of the patient’s body, from healthcare workers (HCWs) to patients, or even between patients <TextLink reference="20"></TextLink>, <TextLink reference="21"></TextLink>.</Pgraph><SubHeadline>Biofilms</SubHeadline><Pgraph>Once medical devices such as catheters or ventilators are inserted into the body, a protein-rich coating forms around them, providing a surface for microorganisms like <Mark2>Staphylococcus</Mark2> <Mark2>aureus</Mark2>, <Mark2>Escherichia coli</Mark2>, <Mark2>Pseudomonas aeruginosa</Mark2> and <Mark2>Candida</Mark2> spp. to attach and thrive <TextLink reference="22"></TextLink>, <TextLink reference="23"></TextLink>. Over time, these bacteria multiply and create biofilms, which mature, break off and spread, entering the bloodstream and potentially leading to severe infections there and elsewhere, e.g.in the urinary tract <TextLink reference="22"></TextLink>. These biofilms make pathogens highly resistant to antibiotics and the body’s own immune system, leading to persistent and hard-to-treat infections <TextLink reference="24"></TextLink>, biofilms are thus also a major cause of infection recurrence <TextLink reference="25"></TextLink>. In many cases, the only way to treat these infections is by removing the infected device <TextLink reference="26"></TextLink>. </Pgraph><SubHeadline>Environmental factors</SubHeadline><Pgraph>Pathogens spread easily in the hospital environment through contaminated hands of HCWs, equipment, and surfaces, especially in patient rooms. Microorganisms such as <Mark2>Staphylococcus</Mark2> <Mark2>aureus</Mark2>, vancomycin-resistant <Mark2>Enterococcus</Mark2> (VRE), <Mark2>Clostridium difficile</Mark2>, <Mark2>Pseudomonas</Mark2> <Mark2>aeruginosa</Mark2>, and <Mark2>Acinetobacter</Mark2> spp. survive for hours to months, depending on factors like location, biofilm formation, and resistance to cleaning products. Moreover, conditions of the hospital environment, for instance, contaminated air-conditioning systems and the layout of healthcare facilities (e.g., crowded units with beds placed close together, installing new wiring for information systems, removing old broken sinks, and fixing elevator shafts), also play a significant role in the transmission of HAIs <TextLink reference="10"></TextLink>, <TextLink reference="27"></TextLink>, <TextLink reference="28"></TextLink>, <TextLink reference="29"></TextLink>, <TextLink reference="30"></TextLink>, <TextLink reference="31"></TextLink>. These factors, along with staffing issues (inadequate nurse-to-patient ratios and the absence of effective IC programs to name just two), can promote the spread of infection<TextGroup><PlainText>s within h</PlainText></TextGroup>ealthcare settings <TextLink reference="10"></TextLink>.</Pgraph><Pgraph>Patient-related factors: The severity of pre-existing or underlying illness, use of immunosuppressive medications, and longer duration of hospital stays, contribute to an increased risk of HAIs by weakening the body’s ability to fight off infections, making patients more vulnerable to pathogens <TextLink reference="10"></TextLink>.</Pgraph><SubHeadline>Antimicrobial resistance in context with HAI</SubHeadline><Pgraph>AMR occurs when pathogens no longer respond to medicines, making infections harder to treat and increasing the risk of severe illness and death. The CDC estimates that 1 in 31 patients will contract a HAI while being treated for an unrelated condition <TextLink reference="32"></TextLink>. HAIs are driving the spread of AMR, which the WHO warns could lead to 10 million deaths a year by 2050, surpassing cancer, while the World Bank warns it could add $1 trillion to global healthcare costs <TextLink reference="32"></TextLink>. While AMR is a natural process, misuse and overuse of antibiotics in humans, livestock, and plants have contributed to the emergence and spread of AMR microorganisms, making HAIs difficult to treat. AMR is a global threat to treating infections and performing life-saving procedures <TextLink reference="33"></TextLink>. Antibiotic-resistant bacteria, including the high-risk ‘ESKAPE’ pathogen<TextGroup><PlainText>s, h</PlainText></TextGroup>ave significantly worsened the global burden of HAIs, especially in developing countries, due to their multidrug resistance and high virulence, making treatment increasingly difficult <TextLink reference="34"></TextLink>, <TextLink reference="35"></TextLink>, <TextLink reference="36"></TextLink>, <TextLink reference="37"></TextLink>. The burden of HAIs is closely linked to AMR, with treatment often requiring broad-spectrum antibiotics due to increased risk of MDR organisms <TextLink reference="7"></TextLink>. <newcolumn/></Pgraph></TextBlock> <TextBlock name="Biofilm and AMR" linked="yes"> <MainHeadline>Biofilm and AMR</MainHeadline><Pgraph>Biofilms contribute to AMR through several mechanisms:</Pgraph><Pgraph><UnorderedList><ListItem level="1">Physical barrier: The slimy matrix of biofilms prevents antibiotics from effectively reaching bacterial cells, reducing drugs' ability to kill or inhibit bacteria inside the biofilm <TextLink reference="26"></TextLink>.</ListItem><ListItem level="1">Recalcitrance: Biofilm-forming bacteria exhibit recalcitrance, meaning they can survive even in the presence of high doses of antibiotics. This is due to the protective environment created by the biofilm structure, which helps bacteria thrive despite drug exposure <TextLink reference="26"></TextLink>.</ListItem><ListItem level="1">Gene transfer: Biofilms facilitate exchange of AMR genes between bacteria, enhancing the spread of resistance within and between bacterial species <TextLink reference="26"></TextLink>.</ListItem><ListItem level="1">Adaptive resistance: Within the biofilm, bacteria can employ various resistance mechanisms like target modification, efflux pumps, and antibiotic inactivation, allowing them to evade both antimicrobial treatments and host immune responses <TextLink reference="26"></TextLink>.</ListItem></UnorderedList></Pgraph></TextBlock> <TextBlock name="Spread of MDRO" linked="yes"> <MainHeadline>Spread of MDRO</MainHeadline><Pgraph><UnorderedList><ListItem level="1"><Mark1>Person-to-person transmission:</Mark1> Pathogens can spread from one person to another through surfaces (e.g., bedrails) or the hands of HCWs if proper IC measures are not followed <TextLink reference="38"></TextLink>.</ListItem><ListItem level="1"><Mark1>Medical procedures and devices:</Mark1> Invasive procedures like surgery and the use of medical devices (e.g., catheters, ventilators) can allow resistant pathogens to enter the body and cause infections <TextLink reference="38"></TextLink>.</ListItem><ListItem level="1"><Mark1>Patient transfers:</Mark1> Resistant pathogens can spread when patients are transferred between healthcare facilities or sent home <TextLink reference="38"></TextLink>.</ListItem><ListItem level="1"><Mark1>Fecal waste:</Mark1> Fecal matter can carry traces of antimicrobials and AMR pathogens. These microorganisms can survive in plumbing and spread through sinks, toilets, and wastewater systems <TextLink reference="38"></TextLink>.</ListItem><ListItem level="1"><Mark1>Challenges in wastewater management:</Mark1> Resistant microorganisms in healthcare wastewater, especially from inpatient facilities, are hard to manage and can spread to treatment plants <TextLink reference="38"></TextLink>.</ListItem><ListItem level="1"><Mark1>Community spread: </Mark1>When resistant pathogens from healthcare settings spill over into communities, they become much harder to control <TextLink reference="38"></TextLink>.</ListItem></UnorderedList></Pgraph></TextBlock> <TextBlock name="Emerging pathogens causing HAI" linked="yes"> <MainHeadline>Emerging pathogens causing HAI</MainHeadline><Pgraph>A growing concern today is the increase in HAIs driven by the spread of emerging drug-resistant pathogens <TextLink reference="39"></TextLink>. Emerging infectious diseases are those that have recently appeared in a population or are rapidly spreading in frequency or location <TextLink reference="32"></TextLink>. While many microbes contribute to AMR, the CDC currently lists <Mark2>Clostridioides difficile</Mark2>, carbapenem-resistant Enterobacteriaceae, drug-resistant <Mark2>Neisseria gonorrhoeae</Mark2>, <Mark2>Candida auris</Mark2>, and carbapenem-resistant <Mark2>Acinetobacter</Mark2> spp. as the most urgent threats <TextLink reference="32"></TextLink>, <TextLink reference="40"></TextLink>. <Mark2>Chryseobacterium indologenes</Mark2>, a hospita<TextGroup><PlainText>l c</PlainText></TextGroup>ontaminant, is emerging as causative agent of HAIs because of increased use of carbapenems and colistin, as it is intrinsically resistance to these antibiotics <TextLink reference="41"></TextLink>. Rare but alarming pathogens such as <Mark2>Stenotrophomonas maltophilia</Mark2>, Shewanella<Mark2> putrefaciens</Mark2>, <Mark2>Ralstonia pickettii</Mark2>, <Mark2>Providencia</Mark2>, <Mark2>Morganella</Mark2>, <Mark2>Nocardia</Mark2>, <Mark2>Elizabethkingia</Mark2>, <Mark2>Proteus</Mark2>, and <Mark2>Burkholderia</Mark2> spp. are also emerging as major causes of HAIs, linked to high mortality rates and public health risks <TextLink reference="42"></TextLink>, <TextLink reference="43"></TextLink>. <Mark2>Stenotrophomonas maltophilia</Mark2> along with <Mark2>Burkholderia cepacia</Mark2>, <Mark2>Ralstonia pickettii</Mark2>, and <Mark2>Elizabethkingia</Mark2> <Mark2>meningoseptica</Mark2> present serious treatment challenges due to their resistance to polymyxins and colistin, while <Mark2>Elizabethkingia</Mark2> spp. are especially tough to treat, being resistant to Gram-negative treatments but susceptible to Gram-positive ones (e.g., vancomycin) <TextLink reference="42"></TextLink>, <TextLink reference="44"></TextLink>, <TextLink reference="45"></TextLink>.</Pgraph></TextBlock> <TextBlock name="HAI prevention and control" linked="yes"> <MainHeadline>HAI prevention and control</MainHeadline><Pgraph>HAIs remain a significant challenge, making infection prevention and control (IPC) essential for protecting patients and HCWs. IPC ensures safety and quality, especially in LMICs facing additional challenges. Strengthening IPC is key to achieving high-quality, safe healthcare and preventing patient harm <TextLink reference="46"></TextLink>. The key strategies for HAI prevention and control are presented in the following.</Pgraph><SubHeadline>Hand hygiene (HH)</SubHeadline><Pgraph>Noncompliance with HH among HCWs is the single most crucial and global issue contributing to HAIs, requiring standardized, multimodal policies, continuous education, and regular monitoring to improve adherence and patient safety <TextLink reference="47"></TextLink>, <TextLink reference="48"></TextLink>. Proper HH with alcohol-based hand rubs before and after handling catheter sites, including insertion, maintenance, or dressing, is the first line of defense in preventing and reducing HAIs, ensuring patient safety and promoting a healthier healthcare environment <TextLink reference="49"></TextLink>, <TextLink reference="50"></TextLink>. Each year, the WHO’s “SAVE LIVES: Clean Your Hands” campaign urges HCWs and patients to prioritize HH, a practice that has become even more vital after the COVID-19 pandemic <TextLink reference="46"></TextLink>.</Pgraph><SubHeadline>Personal protective equipment</SubHeadline><Pgraph>Proper use of maximal sterile barrier precautions, such as sterile gloves, sterile gowns, cap and masks, is crucial for preventing the spread of HAIs, especially when handling potentially infectious materials <TextLink reference="21"></TextLink>.</Pgraph><SubHeadline>Aseptic techniques</SubHeadline><Pgraph>Proper aseptic technique is vital in preventing HAIs during catheter insertion. Non-sterile gloves with a “no-touch” technique suffice for peripheral venous catheters, but sterile gloves are essential for central catheters <TextLink reference="49"></TextLink>. HCWs must be trained in aseptic protocols, as breaches increase infection risks and costs. Routine audits by infectious disease teams are crucial to ensure compliance and enhance patient safety. Prioritizing aseptic technique helps prevent HAIs and improves patient outcomes <TextLink reference="51"></TextLink>.</Pgraph><SubHeadline>Antimicrobial stewardship (AMS)</SubHeadline><Pgraph>With rising antibiotic resistance and limited new drugs, AMS emphasizes the prudent use of antibiotics to improve outcomes, reduce resistance, and cut costs. AMS ensures the right antibiotic, dose, and duration to minimize toxicity and resistance <TextLink reference="47"></TextLink>. The CDC’s Core Elements highlight key strategies: leadership commitment, accountability, drug expertise, action, tracking, reporting, and education. The three primary goals of AMS are: </Pgraph><Pgraph><OrderedList><ListItem level="1" levelPosition="1" numString="1.">ensuring rational and targeted antimicrobial use; </ListItem><ListItem level="1" levelPosition="2" numString="2.">halting overuse and misuse; and </ListItem><ListItem level="1" levelPosition="3" numString="3.">slowing resistance spread. Two main approaches include restricting prescriptive authority and using culture tests to guide treatment, ensuring appropriate use <TextLink reference="52"></TextLink>, <TextLink reference="53"></TextLink>. AMS programs enhance infection cure rates, reduce harm, and help combat AMR <TextLink reference="54"></TextLink>.</ListItem></OrderedList></Pgraph><SubHeadline>Disinfecting surface cleaning</SubHeadline><Pgraph>Inadequate cleaning of hospital surfaces spreads harmful pathogens such as methicillin-resistant <Mark2>Staphylococcus aureus</Mark2> (MRSA), VRE, <Mark2>Clostridium difficile</Mark2>, <Mark2>Acinetobacter</Mark2> spp., and norovirus. Thorough cleaning is essential to reduce infection and maintain safety standards <TextLink reference="54"></TextLink>, <TextLink reference="55"></TextLink>, <TextLink reference="56"></TextLink>.</Pgraph><SubHeadline>Surveillance and monitoring</SubHeadline><Pgraph>HAI surveillance is crucial for guiding effective IPC strategies, and should follow national guidelines. However, these can be customized to each facility’s needs and resources. Both active surveillance (e.g., screening for MRSA, carbapenem-resistant Enterobacteriaceae) and passive surveillance (e.g., lab results, patient records) are essential, tailored to each facility’s needs. Early detection of outbreaks and resistance trends enhances patient safety, reduces infections, and strengthens IC efforts <TextLink reference="57"></TextLink>.</Pgraph><SubHeadline>Education and training</SubHeadline><Pgraph>IPC education is essential for all HCWs, from the newly hired to experienced staff. Ongoing training and audits ensure that staff are up-to-date on best practices and SOPs for IC, including HH, aseptic techniques for invasive procedures, as well as key bundles for CLABSI, CAUTI and VAP, environmental hygiene, reprocessing of medical devices, laundry hygiene, waste management, and water and air hygiene <TextLink reference="54"></TextLink>. Training should be hands-on, using various methods to engage staff and improve knowledge <TextLink reference="58"></TextLink>. Regular updates to training programs tailored to local needs ensure compliance and reduce HAIs, safeguarding patients and HCWs while enhancing care quality <TextLink reference="57"></TextLink>. </Pgraph></TextBlock> <TextBlock name="Innovations in HAI prevention and control" linked="yes"> <MainHeadline>Innovations in HAI prevention and control</MainHeadline><Pgraph>Recent innovations in IPC are making a transformative impact in the fight against HAIs. Below are examples of cutting-edge technologies and approaches that have shown promise in HAI prevention:</Pgraph><Pgraph><UnorderedList><ListItem level="1"><Mark1>Automated hand hygiene surveillance systems (A</Mark1><TextGroup><Mark1>HHS</Mark1></TextGroup><Mark1>S): </Mark1>HH compliance is crucial in preventing HAIs. AHHSS address the challenges of traditional monitoring methods, such as observer bias, the Hawthorne effect and inconsistent training. A recent study showed effectiveness of AHHSS in improving HH compliance, with post-intervention compliance improving from 66%–95% to 77%–90% <TextLink reference="59"></TextLink>, <TextLink reference="60"></TextLink>. AHHSS provide real-time monitoring, instant feedback, and consistent tracking across units, reducing human error and bias. They also integrate with cloud technology, offering easier data access for faster decision-making with minimal IT support <TextLink reference="61"></TextLink>.</ListItem><ListItem level="1"><Mark1>Advanced disinfection technologies: </Mark1>UV-A light offers safe, continuous decontamination in healthcare settings, significantly reducing pathogens such as <Mark2>E. coli</Mark2>, MRSA, and <Mark2>Candida auris</Mark2> without harming patients or staff. Its use in occupied areas can enhance IC <TextLink reference="62"></TextLink>. UV-C light effectively targets MDR pathogens – for instance, MRSA, VRE, and <Mark2>C. difficile</Mark2> – by inducing DNA damage that prevents microbial replication, achieving up to a 4-log reduction in bacterial colonies. The drawback is that it requires vacant rooms, unlike UV-A <TextLink reference="63"></TextLink>, <TextLink reference="64"></TextLink>, <TextLink reference="65"></TextLink>. Novel technologies allow the presence of persons in rooms while UV disinfection is taking place <TextLink reference="66"></TextLink>. Further research is needed to optimize the effectiveness against a broader range of pathogens to fully validate its role in clinical environments.</ListItem><ListItem level="1"><Mark1>Automated reprocessing systems:</Mark1> Improperly cleaned reusable medical devices are a major source of HAIs. Cleaning – the first step, often overlooked – is critical to prevent biofilm formation and ensure effective disinfection. Manual cleaning is error-prone and reliant on staff training, leading to missed steps, especially in understaffed hospitals. Automated reprocessors improve cleaning accuracy and consistency, reducing human error, easing staff strain, and enhancing patient safety. Studies show reprocessing accuracy soars from 1.4% with manual methods to 75.4% with automation <TextLink reference="67"></TextLink>, <TextLink reference="68"></TextLink>.</ListItem><ListItem level="1"><Mark1>Artificial intelligence (AI) and machine learning: </Mark1>HAI prevention through innovations that detect infections before clinical signs appear can stratify patient risk, automate surveillance, include smart monitoring systems, intelligent disinfection robots and enhanced disinfection protocols, all of which shifts IC from reactive to preventive, thus reducing mortality and healthcare costs while improving clinical efficiency <TextLink reference="69"></TextLink>.</ListItem><ListItem level="1"><Mark1>Virtual reality (VR) and augmented reality (AR): </Mark1><TextGroup><PlainText>VR and</PlainText></TextGroup> AR transform IC training by offering immersive, engaging, and realistic experiences that enhance learning, retention, and engagement. These scalable, cost-effective tools boost HCW performance and help reduce HAIs <TextLink reference="70"></TextLink>.</ListItem></UnorderedList></Pgraph></TextBlock> <TextBlock name="Conclusion" linked="yes"> <MainHeadline>Conclusion</MainHeadline><Pgraph>HAIs are a critical clinical issue that directly impacts patient outcomes, healthcare resources, and overall healthcare quality. These infections not only prolong hospital stays but also increase the risk of complications, contribute to rising healthcare costs, and in some cases, lead to preventable deaths. Clinically, HAIs are major cause of morbidity and mortality, especially among immunocompromised patients or those undergoing invasive procedures.</Pgraph><Pgraph>The rise of AMR complicates their management, making timely diagnosis, effective treatment, and IC efforts more challenging. This makes the prevention of HAIs a clinical priority for HCWs at all levels. Understanding the scope of HAIs and implementing evidence-based IPC strategies can significantly improve patient safety, reduce treatment failures, and decrease unnecessary hospital readmissions. Emerging technologies, such as AHHSS, advanced disinfection methods, and AI have shown promise in enhancing IC measures and improving patient outcomes.</Pgraph><Pgraph>This study is crucial for all HCWs, as it emphasizes the importance of structured surveillance, active and passive monitoring, and continuous education on IC practices. By disseminating this information, we can ensure that clinicians, infection prevention teams, and hospital administrators are better equipped to tackle HAIs, improve patient outcomes, and minimize the growing threat of AMR. Knowledge of these issues should be integral to clinical practice, as it empowers healthcare teams to take actionable steps to reduce infections, enhance patient care, and ultimately save lives.</Pgraph></TextBlock> <TextBlock name="Notes" linked="yes"> <MainHeadline>Notes</MainHeadline><SubHeadline>Authors’ ORCIDs </SubHeadline><Pgraph><UnorderedList><ListItem level="1">Anand G: <Hyperlink href="https://orcid.org/0009-0008-0473-389X">https://orcid.org/0009-0008-0473-389X</Hyperlink></ListItem><ListItem level="1">Lahariya R: <Hyperlink href="https://orcid.org/0009-0003-5769-4509">https://orcid.org/0009-0003-5769-4509</Hyperlink></ListItem></UnorderedList></Pgraph><SubHeadline>Funding</SubHeadline><Pgraph>None. </Pgraph><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph></TextBlock> <References linked="yes"> <Reference refNo="1"> <RefAuthor>National Healthcare Safety Network</RefAuthor> <RefTitle></RefTitle> <RefYear>2025</RefYear> <RefBookTitle>Identifying Healthcare-associated Infections (HAI) for NHSN Surveillance</RefBookTitle> <RefPage></RefPage> <RefTotal>National Healthcare Safety Network. Identifying Healthcare-associated Infections (HAI) for NHSN Surveillance. 2025. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsncurrent.pdf</RefTotal> <RefLink>https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsncurrent.pdf</RefLink> </Reference> <Reference refNo="2"> <RefAuthor>CDC</RefAuthor> <RefTitle></RefTitle> <RefYear>2024</RefYear> <RefBookTitle>Healthcare-Associated Infections (HAIs). HAI Prevention and Control for Healthcare</RefBookTitle> <RefPage></RefPage> <RefTotal>CDC. Healthcare-Associated Infections (HAIs). HAI Prevention and Control for Healthcare. 2024 [cited 2025 Aug 11]. Available from: https://www.cdc.gov/healthcare-associated-infections/hcp/prevention-healthcare/index.html</RefTotal> <RefLink>https://www.cdc.gov/healthcare-associated-infections/hcp/prevention-healthcare/index.html</RefLink> </Reference> <Reference refNo="3"> <RefAuthor>Centers for Disease Control and Prevention</RefAuthor> <RefTitle></RefTitle> <RefYear>2019</RefYear> <RefBookTitle>National and State Healthcare-Associated Infections Progress Report</RefBookTitle> <RefPage></RefPage> <RefTotal>Centers for Disease Control and Prevention. National and State Healthcare-Associated Infections Progress Report. 2019. Available from: https://archive.cdc.gov/#/details?q=progress%20report&start=0&rows=10&url=https://www.cdc.gov/hai/data/archive/2019-HAI-progress-report.html</RefTotal> <RefLink>https://archive.cdc.gov/#/details?q=progress%20report&start=0&rows=10&url=https://www.cdc.gov/hai/data/archive/2019-HAI-progress-report.html</RefLink> </Reference> <Reference refNo="4"> <RefAuthor>World Health Organization</RefAuthor> <RefTitle></RefTitle> <RefYear>2010</RefYear> <RefBookTitle>The burden of health care-associated infection worldwide</RefBookTitle> <RefPage></RefPage> <RefTotal>World Health Organization. The burden of health care-associated infection worldwide. 2010. Available from: https://www.who.int/news-room/feature-stories/detail/the-burden-of-health-care-associated-infection-worldwide</RefTotal> <RefLink>https://www.who.int/news-room/feature-stories/detail/the-burden-of-health-care-associated-infection-worldwide</RefLink> </Reference> <Reference refNo="5"> <RefAuthor>World Health Organization</RefAuthor> <RefTitle></RefTitle> <RefYear>2024</RefYear> <RefBookTitle>New report highlights need for sustained investment in infection prevention and control programmes</RefBookTitle> <RefPage></RefPage> <RefTotal>World Health Organization. New report highlights need for sustained investment in infection prevention and control programmes. 2024 [cited 2025 Aug 11]. Available from: https://www.who.int/news/item/29-11-2024-new-report-highlights-need-for-sustained-investment-in-infection-prevention-and-control-programmes</RefTotal> <RefLink>https://www.who.int/news/item/29-11-2024-new-report-highlights-need-for-sustained-investment-in-infection-prevention-and-control-programmes</RefLink> </Reference> <Reference refNo="6"> <RefAuthor>Chakravarthy M</RefAuthor> <RefAuthor>Sengupta S</RefAuthor> <RefAuthor>Singh S</RefAuthor> <RefAuthor>Munshi N</RefAuthor> <RefAuthor>Jose T</RefAuthor> <RefAuthor>Chhaya V</RefAuthor> <RefTitle>Incidence rates of healthcare-associated infections in hospitals: a multicenter, pooled patient data analysis in India</RefTitle> <RefYear>2015</RefYear> <RefJournal>Int J Res Foundation Hosp Healthc Adm</RefJournal> <RefPage>86-90</RefPage> <RefTotal>Chakravarthy M, Sengupta S, Singh S, Munshi N, Jose T, Chhaya V. Incidence rates of healthcare-associated infections in hospitals: a multicenter, pooled patient data analysis in India. Int J Res Foundation Hosp Healthc Adm. 2015 Dec;3(2):86-90. DOI: 10.5005/jp-journals-10035-1042</RefTotal> <RefLink>https://doi.org/10.5005/jp-journals-10035-1042</RefLink> </Reference> <Reference refNo="7"> <RefAuthor>Sartelli M</RefAuthor> <RefAuthor>Marini CP</RefAuthor> <RefAuthor>McNelis J</RefAuthor> <RefAuthor>Coccolini F</RefAuthor> <RefAuthor>Rizzo C</RefAuthor> <RefAuthor>Labricciosa FM</RefAuthor> <RefAuthor>Petrone P</RefAuthor> <RefTitle>Preventing and Controlling Healthcare-Associated Infections: The First Principle of Every Antimicrobial Stewardship Program in Hospital Settings</RefTitle> <RefYear>2024</RefYear> <RefJournal>Antibiotics (Basel)</RefJournal> <RefPage>896</RefPage> <RefTotal>Sartelli M, Marini CP, McNelis J, Coccolini F, Rizzo C, Labricciosa FM, Petrone P. Preventing and Controlling Healthcare-Associated Infections: The First Principle of Every Antimicrobial Stewardship Program in Hospital Settings. Antibiotics (Basel). 2024 Sep;13(9):896. DOI: 10.3390/antibiotics13090896</RefTotal> <RefLink>https://doi.org/10.3390/antibiotics13090896</RefLink> </Reference> <Reference refNo="8"> <RefAuthor>Stone PW</RefAuthor> <RefTitle>Economic burden of healthcare-associated infections: an American perspective</RefTitle> <RefYear>2009</RefYear> <RefJournal>Expert Rev Pharmacoecon Outcomes Res</RefJournal> <RefPage>417-22</RefPage> <RefTotal>Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22. DOI: 10.1586/erp.09.53</RefTotal> <RefLink>https://doi.org/10.1586/erp.09.53</RefLink> </Reference> <Reference refNo="9"> <RefAuthor>De Angelis G</RefAuthor> <RefAuthor>Murthy A</RefAuthor> <RefAuthor>Beyersmann J</RefAuthor> <RefAuthor>Harbarth S</RefAuthor> <RefTitle>Estimating the impact of healthcare-associated infections on length of stay and costs</RefTitle> <RefYear>2010</RefYear> <RefJournal>Clin Microbiol Infect</RefJournal> <RefPage>1729-35</RefPage> <RefTotal>De Angelis G, Murthy A, Beyersmann J, Harbarth S. Estimating the impact of healthcare-associated infections on length of stay and costs. Clin Microbiol Infect. 2010 Dec;16(12):1729-35. DOI: 10.1111/j.1469-0691.2010.03332.x</RefTotal> <RefLink>https://doi.org/10.1111/j.1469-0691.2010.03332.x</RefLink> </Reference> <Reference refNo="10"> <RefAuthor>Al-Tawfiq JA</RefAuthor> <RefAuthor>Tambyah PA</RefAuthor> <RefTitle>Healthcare associated infections (HAI) perspectives</RefTitle> <RefYear>2014</RefYear> <RefJournal>J Infect Public Health</RefJournal> <RefPage>339-44</RefPage> <RefTotal>Al-Tawfiq JA, Tambyah PA. Healthcare associated infections (HAI) perspectives. J Infect Public Health. 2014;7(4):339-44. DOI: 10.1016/j.jiph.2014.04.003</RefTotal> <RefLink>https://doi.org/10.1016/j.jiph.2014.04.003</RefLink> </Reference> <Reference refNo="11"> <RefAuthor>WHO</RefAuthor> <RefTitle></RefTitle> <RefYear>2019</RefYear> <RefBookTitle>WHO regional offices</RefBookTitle> <RefPage></RefPage> <RefTotal>WHO. WHO regional offices. 2019. Available from: https://www.who.int/about/who-we-are/regional-offices</RefTotal> <RefLink>https://www.who.int/about/who-we-are/regional-offices</RefLink> </Reference> <Reference refNo="12"> <RefAuthor>Raoofi S</RefAuthor> <RefAuthor>Pashazadeh Kan F</RefAuthor> <RefAuthor>Rafiei S</RefAuthor> <RefAuthor>Hosseinipalangi Z</RefAuthor> <RefAuthor>Noorani Mejareh Z</RefAuthor> <RefAuthor>Khani S</RefAuthor> <RefAuthor>Abdollahi B</RefAuthor> <RefAuthor>Seyghalani Talab F</RefAuthor> <RefAuthor>Sanaei M</RefAuthor> <RefAuthor>Zarabi F</RefAuthor> <RefAuthor>Dolati Y</RefAuthor> <RefAuthor>Ahmadi N</RefAuthor> <RefAuthor>Raoofi N</RefAuthor> <RefAuthor>Sarhadi Y</RefAuthor> <RefAuthor>Masoumi M</RefAuthor> <RefAuthor>Sadat Hosseini B</RefAuthor> <RefAuthor>Vali N</RefAuthor> <RefAuthor>Gholamali N</RefAuthor> <RefAuthor>Asadi S</RefAuthor> <RefAuthor>Ahmadi S</RefAuthor> <RefAuthor>Ahmadi B</RefAuthor> <RefAuthor>Beiramy Chomalu Z</RefAuthor> <RefAuthor>Asadollahi E</RefAuthor> <RefAuthor>Rajabi M</RefAuthor> <RefAuthor>Gharagozloo D</RefAuthor> <RefAuthor>Nejatifar Z</RefAuthor> <RefAuthor>Soheylirad R</RefAuthor> <RefAuthor>Jalali S</RefAuthor> <RefAuthor>Aghajani F</RefAuthor> <RefAuthor>Navidriahy M</RefAuthor> <RefAuthor>Deylami S</RefAuthor> <RefAuthor>Nasiri M</RefAuthor> <RefAuthor>Zareei M</RefAuthor> <RefAuthor>Golmohammadi Z</RefAuthor> <RefAuthor>Shabani H</RefAuthor> <RefAuthor>Torabi F</RefAuthor> <RefAuthor>Shabaninejad H</RefAuthor> <RefAuthor>Nemati A</RefAuthor> <RefAuthor>Amerzadeh M</RefAuthor> <RefAuthor>Aryankhesal A</RefAuthor> <RefAuthor>Ghashghaee A</RefAuthor> <RefTitle>Global prevalence of nosocomial infection: A systematic review and meta-analysis</RefTitle> <RefYear>2023</RefYear> <RefJournal>PLoS One</RefJournal> <RefPage>e0274248</RefPage> <RefTotal>Raoofi S, Pashazadeh Kan F, Rafiei S, Hosseinipalangi Z, Noorani Mejareh Z, Khani S, Abdollahi B, Seyghalani Talab F, Sanaei M, Zarabi F, Dolati Y, Ahmadi N, Raoofi N, Sarhadi Y, Masoumi M, Sadat Hosseini B, Vali N, Gholamali N, Asadi S, Ahmadi S, Ahmadi B, Beiramy Chomalu Z, Asadollahi E, Rajabi M, Gharagozloo D, Nejatifar Z, Soheylirad R, Jalali S, Aghajani F, Navidriahy M, Deylami S, Nasiri M, Zareei M, Golmohammadi Z, Shabani H, Torabi F, Shabaninejad H, Nemati A, Amerzadeh M, Aryankhesal A, Ghashghaee A. Global prevalence of nosocomial infection: A systematic review and meta-analysis. PLoS One. 2023;18(1):e0274248. DOI: 10.1371/journal.pone.0274248</RefTotal> <RefLink>https://doi.org/10.1371/journal.pone.0274248</RefLink> </Reference> <Reference refNo="13"> <RefAuthor>Murhekar MV</RefAuthor> <RefAuthor>Kumar CG</RefAuthor> <RefTitle>Health-care-associated infection surveillance in India</RefTitle> <RefYear>2022</RefYear> <RefJournal>Lancet Glob Health</RefJournal> <RefPage>e1222-e1223</RefPage> <RefTotal>Murhekar MV, Kumar CG. Health-care-associated infection surveillance in India. Lancet Glob Health. 2022 Sep;10(9):e1222-e1223. DOI: 10.1016/S2214-109X(22)00317-5</RefTotal> <RefLink>https://doi.org/10.1016/S2214-109X(22)00317-5</RefLink> </Reference> <Reference refNo="14"> <RefAuthor>NHSN</RefAuthor> <RefTitle></RefTitle> <RefYear>2020</RefYear> <RefBookTitle>CDC/NHSN Surveillance Definitions for Specific Types of Infections</RefBookTitle> <RefPage></RefPage> <RefTotal>NHSN. CDC/NHSN Surveillance Definitions for Specific Types of Infections. 2020. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf</RefTotal> <RefLink>https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf</RefLink> </Reference> <Reference refNo="15"> <RefAuthor>ECDC</RefAuthor> <RefTitle></RefTitle> <RefYear></RefYear> <RefBookTitle>Surveillance of healthcare-associated infections and prevention indicators in European intensive care units HAI-Net ICU protocol, version 2.2. 2017</RefBookTitle> <RefPage></RefPage> <RefTotal>ECDC. Surveillance of healthcare-associated infections and prevention indicators in European intensive care units HAI-Net ICU protocol, version 2.2. 2017. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/HAI-Net-ICU-protocol-v2.2_0.pdf</RefTotal> <RefLink>https://www.ecdc.europa.eu/sites/default/files/documents/HAI-Net-ICU-protocol-v2.2_0.pdf</RefLink> </Reference> <Reference refNo="16"> <RefAuthor>Centers for Disease control and Prevention</RefAuthor> <RefTitle></RefTitle> <RefYear>2022</RefYear> <RefBookTitle>Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and non-central line-associated Bloodstream Infection)</RefBookTitle> <RefPage></RefPage> <RefTotal>Centers for Disease control and Prevention. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and non-central line-associated Bloodstream Infection). 2022. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf</RefTotal> <RefLink>https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf</RefLink> </Reference> <Reference refNo="17"> <RefAuthor>El-Saed A</RefAuthor> <RefAuthor>Balkhy HH</RefAuthor> <RefAuthor>Weber DJ</RefAuthor> <RefTitle>Benchmarking local healthcare-associated infections: available benchmarks and interpretation challenges</RefTitle> <RefYear>2013</RefYear> <RefJournal>J Infect Public Health</RefJournal> <RefPage>323-30</RefPage> <RefTotal>El-Saed A, Balkhy HH, Weber DJ. Benchmarking local healthcare-associated infections: available benchmarks and interpretation challenges. J Infect Public Health. 2013 Oct;6(5):323-30. DOI: 10.1016/j.jiph.2013.05.001</RefTotal> <RefLink>https://doi.org/10.1016/j.jiph.2013.05.001</RefLink> </Reference> <Reference refNo="18"> <RefAuthor>Bennett EE</RefAuthor> <RefAuthor>VanBuren J</RefAuthor> <RefAuthor>Holubkov R</RefAuthor> <RefAuthor>Bratton SL</RefAuthor> <RefTitle>Presence of Invasive Devices and Risks of Healthcare-Associated Infections and Sepsis</RefTitle> <RefYear>2018</RefYear> <RefJournal>J Pediatr Intensive Care</RefJournal> <RefPage>188-95</RefPage> <RefTotal>Bennett EE, VanBuren J, Holubkov R, Bratton SL. Presence of Invasive Devices and Risks of Healthcare-Associated Infections and Sepsis. J Pediatr Intensive Care. 2018 Dec;7(4):188-95. DOI: 10.1055/s-0038-1656535</RefTotal> <RefLink>https://doi.org/10.1055/s-0038-1656535</RefLink> </Reference> <Reference refNo="19"> <RefAuthor>von Eiff C</RefAuthor> <RefAuthor>Jansen B</RefAuthor> <RefAuthor>Kohnen W</RefAuthor> <RefAuthor>Becker K</RefAuthor> <RefTitle>Infections associated with medical devices: pathogenesis, management and prophylaxis</RefTitle> <RefYear>2005</RefYear> <RefJournal>Drugs</RefJournal> <RefPage>179-214</RefPage> <RefTotal>von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs. 2005;65(2):179-214. DOI: 10.2165/00003495-200565020-00003</RefTotal> <RefLink>https://doi.org/10.2165/00003495-200565020-00003</RefLink> </Reference> <Reference refNo="20"> <RefAuthor>Cooper T</RefAuthor> <RefAuthor>Tew L</RefAuthor> <RefAuthor>Randle J</RefAuthor> <RefAuthor>Percival SL</RefAuthor> <RefTitle>Invasive Devices</RefTitle> <RefYear>2024</RefYear> <RefBookTitle>Biofilms in Infection Prevention and Control</RefBookTitle> <RefPage>91-126</RefPage> <RefTotal>Cooper T, Tew L, Randle J, Percival SL. Invasive Devices. In: Percival SL, Williams DW, Randle J, Cooper T, Williams DW, editors. Biofilms in Infection Prevention and Control. Boston: Elsevier;2024. p. 91-126. DOI: 10.1016/B978-0-12-397043-5.00007-4</RefTotal> <RefLink>https://doi.org/10.1016/B978-0-12-397043-5.00007-4</RefLink> </Reference> <Reference refNo="21"> <RefAuthor>Collins AS</RefAuthor> <RefTitle>Preventing Health Care–Associated Infections</RefTitle> <RefYear>2008</RefYear> <RefBookTitle>Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Chapter 41</RefBookTitle> <RefPage></RefPage> <RefTotal>Collins AS. Preventing Health Care–Associated Infections. In: Hughes RG, editor. Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Chapter 41. Rockville (MD:Agency for Healthcare Research and Quality (US);2008.</RefTotal> </Reference> <Reference refNo="22"> <RefAuthor>Di Domenico EG</RefAuthor> <RefAuthor>Oliva A</RefAuthor> <RefAuthor>Guembe M</RefAuthor> <RefTitle>The Current Knowledge on the Pathogenesis of Tissue and Medical Device-Related Biofilm Infections</RefTitle> <RefYear>2022</RefYear> <RefJournal>Microorganisms</RefJournal> <RefPage>1259</RefPage> <RefTotal>Di Domenico EG, Oliva A, Guembe M. The Current Knowledge on the Pathogenesis of Tissue and Medical Device-Related Biofilm Infections. Microorganisms. 2022 Jun;10(7):1259. DOI: 10.3390/microorganisms10071259</RefTotal> <RefLink>https://doi.org/10.3390/microorganisms10071259</RefLink> </Reference> <Reference refNo="23"> <RefAuthor>Dadi NCT</RefAuthor> <RefAuthor>Radochová B</RefAuthor> <RefAuthor>Vargová J</RefAuthor> <RefAuthor>Bujdáková H</RefAuthor> <RefTitle>Impact of Healthcare-Associated Infections Connected to Medical Devices-An Update</RefTitle> <RefYear>2021</RefYear> <RefJournal>Microorganisms</RefJournal> <RefPage>2332</RefPage> <RefTotal>Dadi NCT, Radochová B, Vargová J, Bujdáková H. Impact of Healthcare-Associated Infections Connected to Medical Devices-An Update. Microorganisms. 2021 Nov;9(11):2332. DOI: 10.3390/microorganisms9112332</RefTotal> <RefLink>https://doi.org/10.3390/microorganisms9112332</RefLink> </Reference> <Reference refNo="24"> <RefAuthor>Fleming D</RefAuthor> <RefAuthor>Rumbaugh KP</RefAuthor> <RefTitle>Approaches to Dispersing Medical Biofilms</RefTitle> <RefYear>2017</RefYear> <RefJournal>Microorganisms</RefJournal> <RefPage>15</RefPage> <RefTotal>Fleming D, Rumbaugh KP. Approaches to Dispersing Medical Biofilms. Microorganisms. 2017 Apr;5(2):15. DOI: 10.3390/microorganisms5020015</RefTotal> <RefLink>https://doi.org/10.3390/microorganisms5020015</RefLink> </Reference> <Reference refNo="26"> <RefAuthor>Mishra A</RefAuthor> <RefAuthor>Aggarwal A</RefAuthor> <RefAuthor>Khan F</RefAuthor> <RefTitle>Medical Device-Associated Infections Caused by Biofilm-Forming Microbial Pathogens and Controlling Strategies</RefTitle> <RefYear>2024</RefYear> <RefJournal>Antibiotics (Basel)</RefJournal> <RefPage>623</RefPage> <RefTotal>Mishra A, Aggarwal A, Khan F. Medical Device-Associated Infections Caused by Biofilm-Forming Microbial Pathogens and Controlling Strategies. Antibiotics (Basel). 2024 Jul;13(7):623. DOI: 10.3390/antibiotics13070623</RefTotal> <RefLink>https://doi.org/10.3390/antibiotics13070623</RefLink> </Reference> <Reference refNo="25"> <RefAuthor>Svensson Malchau K</RefAuthor> <RefAuthor>Tillander J</RefAuthor> <RefAuthor>Zaborowska M</RefAuthor> <RefAuthor>Hoffman M</RefAuthor> <RefAuthor>Lasa I</RefAuthor> <RefAuthor>Thomsen P</RefAuthor> <RefAuthor>Malchau H</RefAuthor> <RefAuthor>Rolfson O</RefAuthor> <RefAuthor>Trobos M</RefAuthor> <RefTitle>Biofilm properties in relation to treatment outcome in patients with first-time periprosthetic hip or knee joint infection</RefTitle> <RefYear>2021</RefYear> <RefJournal>J Orthop Translat</RefJournal> <RefPage>31-40</RefPage> <RefTotal>Svensson Malchau K, Tillander J, Zaborowska M, Hoffman M, Lasa I, Thomsen P, Malchau H, Rolfson O, Trobos M. Biofilm properties in relation to treatment outcome in patients with first-time periprosthetic hip or knee joint infection. J Orthop Translat. 2021 Sep;30:31-40. DOI: 10.1016/j.jot.2021.05.008</RefTotal> <RefLink>https://doi.org/10.1016/j.jot.2021.05.008</RefLink> </Reference> <Reference refNo="27"> <RefAuthor>CDC</RefAuthor> <RefTitle></RefTitle> <RefYear>2003</RefYear> <RefBookTitle>Infection Control. A. Introduction</RefBookTitle> <RefPage></RefPage> <RefTotal>CDC. Infection Control. A. Introduction. 2003. Available from: https://www.cdc.gov/infection-control/hcp/environmental-control/introduction.html</RefTotal> <RefLink>https://www.cdc.gov/infection-control/hcp/environmental-control/introduction.html</RefLink> </Reference> <Reference refNo="28"> <RefAuthor>Villamaria FC</RefAuthor> <RefAuthor>Berlanga G</RefAuthor> <RefAuthor>Liao IC</RefAuthor> <RefAuthor>Ganachari-Mallappa N</RefAuthor> <RefAuthor>Stock EM</RefAuthor> <RefAuthor>Zeber JE</RefAuthor> <RefAuthor>Jinadatha C</RefAuthor> <RefTitle>Comparison of Environmental MRSA Levels on High-Touch Surfaces in Contact Isolation and Noncontact Isolation Patient Rooms</RefTitle> <RefYear>2015</RefYear> <RefJournal>Infect Control Hosp Epidemiol</RefJournal> <RefPage>1472-5</RefPage> <RefTotal>Villamaria FC, Berlanga G, Liao IC, Ganachari-Mallappa N, Stock EM, Zeber JE, Jinadatha C. Comparison of Environmental MRSA Levels on High-Touch Surfaces in Contact Isolation and Noncontact Isolation Patient Rooms. Infect Control Hosp Epidemiol. 2015 Dec;36(12):1472-5. DOI: 10.1017/ice.2015.207</RefTotal> <RefLink>https://doi.org/10.1017/ice.2015.207</RefLink> </Reference> <Reference refNo="29"> <RefAuthor>Chirca I</RefAuthor> <RefTitle>The hospital environment and its microbial burden: challenges and solutions</RefTitle> <RefYear>2019</RefYear> <RefJournal>Future Microbiol</RefJournal> <RefPage>1007-10</RefPage> <RefTotal>Chirca I. The hospital environment and its microbial burden: challenges and solutions. Future Microbiol. 2019 Aug;14:1007-10. DOI: 10.2217/fmb-2019-0140</RefTotal> <RefLink>https://doi.org/10.2217/fmb-2019-0140</RefLink> </Reference> <Reference refNo="30"> <RefAuthor>Otter JA</RefAuthor> <RefAuthor>Yezli S</RefAuthor> <RefAuthor>Salkeld JA</RefAuthor> <RefAuthor>French GL</RefAuthor> <RefTitle>Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings</RefTitle> <RefYear>2013</RefYear> <RefJournal>Am J Infect Control</RefJournal> <RefPage>S6-11</RefPage> <RefTotal>Otter JA, Yezli S, Salkeld JA, French GL. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. Am J Infect Control. 2013 May;41(5 Suppl):S6-11. DOI: 10.1016/j.ajic.2012.12.004</RefTotal> <RefLink>https://doi.org/10.1016/j.ajic.2012.12.004</RefLink> </Reference> <Reference refNo="31"> <RefAuthor>Kramer A</RefAuthor> <RefAuthor>Lexow F</RefAuthor> <RefAuthor>Bludau A</RefAuthor> <RefAuthor>Köster AM</RefAuthor> <RefAuthor>Misailovski M</RefAuthor> <RefAuthor>Seifert U</RefAuthor> <RefAuthor>Eggers M</RefAuthor> <RefAuthor>Rutala W</RefAuthor> <RefAuthor>Dancer SJ</RefAuthor> <RefAuthor>Scheithauer S</RefAuthor> <RefTitle>How long do bacteria, fungi, protozoa, and viruses retain their replication capacity on inanimate surfaces? A systematic review examining environmental resilience versus healthcare-associated infection risk by "fomite-borne risk assessment"</RefTitle> <RefYear>2024</RefYear> <RefJournal>Clin Microbiol Rev</RefJournal> <RefPage>e0018623</RefPage> <RefTotal>Kramer A, Lexow F, Bludau A, Köster AM, Misailovski M, Seifert U, Eggers M, Rutala W, Dancer SJ, Scheithauer S. How long do bacteria, fungi, protozoa, and viruses retain their replication capacity on inanimate surfaces? A systematic review examining environmental resilience versus healthcare-associated infection risk by "fomite-borne risk assessment". Clin Microbiol Rev. 2024 Dec;37(4):e0018623. DOI: 10.1128/cmr.00186-23</RefTotal> <RefLink>https://doi.org/10.1128/cmr.00186-23</RefLink> </Reference> <Reference refNo="32"> <RefAuthor>Rohde RE</RefAuthor> <RefTitle></RefTitle> <RefYear></RefYear> <RefBookTitle>Emerging Pathogens: A Look Toward 2024</RefBookTitle> <RefPage></RefPage> <RefTotal>Rohde RE. Emerging Pathogens: A Look Toward 2024. Available from: https://www.clinicallab.com/emerging-pathogens-a-look-toward-2024-27676</RefTotal> <RefLink>https://www.clinicallab.com/emerging-pathogens-a-look-toward-2024-27676</RefLink> </Reference> <Reference refNo="33"> <RefAuthor>World Health Organization</RefAuthor> <RefTitle></RefTitle> <RefYear>2023</RefYear> <RefBookTitle>Antimicrobial Resistance</RefBookTitle> <RefPage></RefPage> <RefTotal>World Health Organization. Antimicrobial Resistance. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance</RefTotal> <RefLink>https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance</RefLink> </Reference> <Reference refNo="34"> <RefAuthor>Rice LB</RefAuthor> <RefTitle>Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE</RefTitle> <RefYear>2008</RefYear> <RefJournal>J Infect Dis</RefJournal> <RefPage>1079-81</RefPage> <RefTotal>Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008 Apr;197(8):1079-81. DOI: 10.1086/533452</RefTotal> <RefLink>https://doi.org/10.1086/533452</RefLink> </Reference> <Reference refNo="35"> <RefAuthor>Agaba P</RefAuthor> <RefAuthor>Tumukunde J</RefAuthor> <RefAuthor>Tindimwebwa JVB</RefAuthor> <RefAuthor>Kwizera A</RefAuthor> <RefTitle>Nosocomial bacterial infections and their antimicrobial susceptibility patterns among patients in Ugandan intensive care units: a cross sectional study</RefTitle> <RefYear>2017</RefYear> <RefJournal>BMC Res Notes</RefJournal> <RefPage>349</RefPage> <RefTotal>Agaba P, Tumukunde J, Tindimwebwa JVB, Kwizera A. Nosocomial bacterial infections and their antimicrobial susceptibility patterns among patients in Ugandan intensive care units: a cross sectional study. BMC Res Notes. 2017 Jul;10(1):349. DOI: 10.1186/s13104-017-2695-5</RefTotal> <RefLink>https://doi.org/10.1186/s13104-017-2695-5</RefLink> </Reference> <Reference refNo="36"> <RefAuthor>Pastan I</RefAuthor> <RefAuthor>Gottesman MM</RefAuthor> <RefTitle>Multidrug resistance</RefTitle> <RefYear>1991</RefYear> <RefJournal>Annu Rev Med</RefJournal> <RefPage>277-86</RefPage> <RefTotal>Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med. 1991;42:277-86. DOI: 10.1146/annurev.me.42.020191.001425</RefTotal> <RefLink>https://doi.org/10.1146/annurev.me.42.020191.001425</RefLink> </Reference> <Reference refNo="37"> <RefAuthor>Founou RC</RefAuthor> <RefAuthor>Founou LL</RefAuthor> <RefAuthor>Essack SY</RefAuthor> <RefTitle>Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis</RefTitle> <RefYear>2017</RefYear> <RefJournal>PLoS One</RefJournal> <RefPage>e0189621</RefPage> <RefTotal>Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. PLoS One. 2017;12(12):e0189621. DOI: 10.1371/journal.pone.0189621</RefTotal> <RefLink>https://doi.org/10.1371/journal.pone.0189621</RefLink> </Reference> <Reference refNo="38"> <RefAuthor>CDC</RefAuthor> <RefTitle></RefTitle> <RefYear>2024</RefYear> <RefBookTitle>Antimicrobial Resistance in Health Care: Causes and How It Spreads</RefBookTitle> <RefPage></RefPage> <RefTotal>CDC. Antimicrobial Resistance in Health Care: Causes and How It Spreads. 2024. Available from: https://www.cdc.gov/antimicrobial-resistance/causes/healthcare.html</RefTotal> <RefLink>https://www.cdc.gov/antimicrobial-resistance/causes/healthcare.html</RefLink> </Reference> <Reference refNo="39"> <RefAuthor>Saikeerthana D</RefAuthor> <RefAuthor>Prabha P</RefAuthor> <RefAuthor>Vijayashree V</RefAuthor> <RefAuthor>Krishna GNM</RefAuthor> <RefTitle>Overview of pathogens causing nosocomial infections in various wards of a tertiary health care hospital and their antimicrobial susceptibility pattern-a prospective surveillance study</RefTitle> <RefYear>2021</RefYear> <RefJournal>J Pure Appl Microbiol</RefJournal> <RefPage>1940-46</RefPage> <RefTotal>Saikeerthana D, Prabha P, Vijayashree V, Krishna GNM. Overview of pathogens causing nosocomial infections in various wards of a tertiary health care hospital and their antimicrobial susceptibility pattern-a prospective surveillance study. J Pure Appl Microbiol. 2021 Oct;15(4):1940-46. DOI: 10.22207/JPAM.15.4.15</RefTotal> <RefLink>https://doi.org/10.22207/JPAM.15.4.15</RefLink> </Reference> <Reference refNo="40"> <RefAuthor>Piedrahita CT</RefAuthor> <RefAuthor>Cadnum JL</RefAuthor> <RefAuthor>Jencson AL</RefAuthor> <RefAuthor>Shaikh AA</RefAuthor> <RefAuthor>Ghannoum MA</RefAuthor> <RefAuthor>Donskey CJ</RefAuthor> <RefTitle>Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species</RefTitle> <RefYear>2017</RefYear> <RefJournal>Infect Control Hosp Epidemiol</RefJournal> <RefPage>1107-9</RefPage> <RefTotal>Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species. Infect Control Hosp Epidemiol. 2017 Sep;38(9):1107-9. DOI: 10.1017/ice.2017.127</RefTotal> <RefLink>https://doi.org/10.1017/ice.2017.127</RefLink> </Reference> <Reference refNo="41"> <RefAuthor>Jain V</RefAuthor> <RefAuthor>Sahu C</RefAuthor> <RefAuthor>Afzal Hussain NAF</RefAuthor> <RefAuthor>Ghar M</RefAuthor> <RefAuthor>Prasad KN</RefAuthor> <RefTitle>The Era of Device Colonizers: Infections from a Tertiary Care Center in North India</RefTitle> <RefYear>2018</RefYear> <RefJournal>Indian J Crit Care Med</RefJournal> <RefPage>537-40</RefPage> <RefTotal>Jain V, Sahu C, Afzal Hussain NAF, Ghar M, Prasad KN. The Era of Device Colonizers: Infections from a Tertiary Care Center in North India. Indian J Crit Care Med. 2018 Jul;22(7):537-40. DOI: 10.4103/ijccm.IJCCM_24_18</RefTotal> <RefLink>https://doi.org/10.4103/ijccm.IJCCM_24_18</RefLink> </Reference> <Reference refNo="42"> <RefAuthor>Sahu MK</RefAuthor> <RefAuthor>George N</RefAuthor> <RefAuthor>Rastogi N</RefAuthor> <RefAuthor>Chalatti Bipin</RefAuthor> <RefAuthor>Singh SP</RefAuthor> <RefTitle>Uncommon pathogens causing hospital-acquired infections in postoperative cardiac surgical patients</RefTitle> <RefYear>2019</RefYear> <RefJournal>J Cardiac Crit Care TSS</RefJournal> <RefPage>89-96</RefPage> <RefTotal>Sahu MK, George N, Rastogi N, Chalatti Bipin, Singh SP. Uncommon pathogens causing hospital-acquired infections in postoperative cardiac surgical patients. J Cardiac Crit Care TSS. 2019 March 1;3(02):89-96. DOI: 10.1055/s-0040-1705080</RefTotal> <RefLink>https://doi.org/10.1055/s-0040-1705080</RefLink> </Reference> <Reference refNo="43"> <RefAuthor>Looney WJ</RefAuthor> <RefTitle>Role of Stenotrophomonas maltophilia in hospital-acquired infection</RefTitle> <RefYear>2005</RefYear> <RefJournal>Br J Biomed Sci</RefJournal> <RefPage>145-54; quiz 1 p following 154</RefPage> <RefTotal>Looney WJ. Role of Stenotrophomonas maltophilia in hospital-acquired infection. Br J Biomed Sci. 2005;62(3):145-54; quiz 1 p following 154. DOI: 10.1080/09674845.2005.11732702</RefTotal> <RefLink>https://doi.org/10.1080/09674845.2005.11732702</RefLink> </Reference> <Reference refNo="44"> <RefAuthor>Keaton A</RefAuthor> <RefAuthor>Fike L</RefAuthor> <RefAuthor>Spicer K</RefAuthor> <RefAuthor>Kallen A</RefAuthor> <RefAuthor>Perkins K</RefAuthor> <RefTitle>Healthcare-associated Stenotrophomonas maltophilia infections in the United States, 2018-2022</RefTitle> <RefYear>2023</RefYear> <RefJournal>Antimicrob Steward Healthc Epidemiol</RefJournal> <RefPage>s89</RefPage> <RefTotal>Keaton A, Fike L, Spicer K, Kallen A, Perkins K. Healthcare-associated Stenotrophomonas maltophilia infections in the United States, 2018-2022. Antimicrob Steward Healthc Epidemiol. 2023 Sep 29;3(Suppl 2):s89. DOI: 10.1017/ash.2023.352</RefTotal> <RefLink>https://doi.org/10.1017/ash.2023.352</RefLink> </Reference> <Reference refNo="45"> <RefAuthor>Varshini MK</RefAuthor> <RefAuthor>Ganesan V</RefAuthor> <RefAuthor>Sundaramurthy R</RefAuthor> <RefAuthor>Rajendran T</RefAuthor> <RefTitle>Risk Factors and Clinical Outcomes of Infections: Scenario in a Tertiary Care Center from South India</RefTitle> <RefYear>2022</RefYear> <RefJournal>Indian J Crit Care Med</RefJournal> <RefPage>935-7</RefPage> <RefTotal>Varshini MK, Ganesan V, Sundaramurthy R, Rajendran T. Risk Factors and Clinical Outcomes of Infections: Scenario in a Tertiary Care Center from South India. Indian J Crit Care Med. 2022 Aug;26(8):935-7. DOI: 10.5005/jp-journals-10071-24288</RefTotal> <RefLink>https://doi.org/10.5005/jp-journals-10071-24288</RefLink> </Reference> <Reference refNo="46"> <RefAuthor>World Health Organization</RefAuthor> <RefTitle></RefTitle> <RefYear>2023</RefYear> <RefBookTitle>Infection Prevention and Control</RefBookTitle> <RefPage></RefPage> <RefTotal>World Health Organization. Infection Prevention and Control. 2023. Available from: https://www.who.int/health-topics/infection-prevention-and-control#tab=tab_1</RefTotal> <RefLink>https://www.who.int/health-topics/infection-prevention-and-control#tab=tab_1</RefLink> </Reference> <Reference refNo="47"> <RefAuthor>Haque M</RefAuthor> <RefAuthor>McKimm J</RefAuthor> <RefAuthor>Sartelli M</RefAuthor> <RefAuthor>Dhingra S</RefAuthor> <RefAuthor>Labricciosa FM</RefAuthor> <RefAuthor>Islam S</RefAuthor> <RefAuthor>Jahan D</RefAuthor> <RefAuthor>Nusrat T</RefAuthor> <RefAuthor>Chowdhury TS</RefAuthor> <RefAuthor>Coccolini F</RefAuthor> <RefAuthor>Iskandar K</RefAuthor> <RefAuthor>Catena F</RefAuthor> <RefAuthor>Charan J</RefAuthor> <RefTitle>Strategies to Prevent Healthcare-Associated Infections: A Narrative Overview</RefTitle> <RefYear>2020</RefYear> <RefJournal>Risk Manag Healthc Policy</RefJournal> <RefPage>1765-80</RefPage> <RefTotal>Haque M, McKimm J, Sartelli M, Dhingra S, Labricciosa FM, Islam S, Jahan D, Nusrat T, Chowdhury TS, Coccolini F, Iskandar K, Catena F, Charan J. Strategies to Prevent Healthcare-Associated Infections: A Narrative Overview. Risk Manag Healthc Policy. 2020;13:1765-80. DOI: 10.2147/RMHP.S269315</RefTotal> <RefLink>https://doi.org/10.2147/RMHP.S269315</RefLink> </Reference> <Reference refNo="48"> <RefAuthor>Australian Government</RefAuthor> <RefTitle></RefTitle> <RefYear></RefYear> <RefBookTitle>Infection prevention and control 2017</RefBookTitle> <RefPage></RefPage> <RefTotal>Australian Government. Infection prevention and control 2017. Available from: https://www.amr.gov.au/what-you-can-do/hospitals/infection-prevention-and-control</RefTotal> <RefLink>https://www.amr.gov.au/what-you-can-do/hospitals/infection-prevention-and-control</RefLink> </Reference> <Reference refNo="49"> <RefAuthor>CDC</RefAuthor> <RefTitle></RefTitle> <RefYear>2024</RefYear> <RefBookTitle>Background Information: Strategies for Prevention of Catheter-Related Infections in Adult and Pediatric Patients</RefBookTitle> <RefPage></RefPage> <RefTotal>CDC. Background Information: Strategies for Prevention of Catheter-Related Infections in Adult and Pediatric Patients. 2024. Available from: https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/prevention-strategies.html.</RefTotal> <RefLink>https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/prevention-strategies.html</RefLink> </Reference> <Reference refNo="50"> <RefAuthor>Tartari E</RefAuthor> <RefAuthor>Bellissimo-Rodrigues F</RefAuthor> <RefAuthor>Pires D</RefAuthor> <RefAuthor>Fankhauser C</RefAuthor> <RefAuthor>Lotfinejad N</RefAuthor> <RefAuthor>Saito H</RefAuthor> <RefAuthor>Suchomel M</RefAuthor> <RefAuthor>Kramer A</RefAuthor> <RefAuthor>Allegranzi B</RefAuthor> <RefAuthor>Boyce J</RefAuthor> <RefAuthor>Sax H</RefAuthor> <RefAuthor>Stewardson AJ</RefAuthor> <RefAuthor>Pittet D</RefAuthor> <RefAuthor> ICPIC Alcohol-Based Handrub Task Force</RefAuthor> <RefTitle>Updates and future directions regarding hand hygiene in the healthcare setting: insights from the 3rd ICPIC alcohol-based handrub (ABHR) task force</RefTitle> <RefYear>2024</RefYear> <RefJournal>Antimicrob Resist Infect Control</RefJournal> <RefPage>26</RefPage> <RefTotal>Tartari E, Bellissimo-Rodrigues F, Pires D, Fankhauser C, Lotfinejad N, Saito H, Suchomel M, Kramer A, Allegranzi B, Boyce J, Sax H, Stewardson AJ, Pittet D; ICPIC Alcohol-Based Handrub Task Force. Updates and future directions regarding hand hygiene in the healthcare setting: insights from the 3rd ICPIC alcohol-based handrub (ABHR) task force. Antimicrob Resist Infect Control. 2024 Feb;13(1):26. DOI: 10.1186/s13756-024-01374-9</RefTotal> <RefLink>https://doi.org/10.1186/s13756-024-01374-9</RefLink> </Reference> <Reference refNo="51"> <RefAuthor>Tennant K</RefAuthor> <RefAuthor>Rivers CL</RefAuthor> <RefTitle></RefTitle> <RefYear></RefYear> <RefBookTitle>Sterile Technique</RefBookTitle> <RefPage></RefPage> <RefTotal>Tennant K, Rivers CL. Sterile Technique. [updated 2022 Sep 19]. StatPearls. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459175/</RefTotal> <RefLink>https://www.ncbi.nlm.nih.gov/books/NBK459175/</RefLink> </Reference> <Reference refNo="52"> <RefAuthor>Centers for Disease Control and Prevention</RefAuthor> <RefTitle></RefTitle> <RefYear></RefYear> <RefBookTitle>Antibiotic use in the United States, 2024 update: Progress and opportunities</RefBookTitle> <RefPage></RefPage> <RefTotal>Centers for Disease Control and Prevention. Antibiotic use in the United States, 2024 update: Progress and opportunities. Available from: https://www.cdc.gov/antibiotic-use/hcp/data-research/stewardship-report.html</RefTotal> <RefLink>https://www.cdc.gov/antibiotic-use/hcp/data-research/stewardship-report.html</RefLink> </Reference> <Reference refNo="53"> <RefAuthor>Centers for Disease Control and Prevention</RefAuthor> <RefTitle></RefTitle> <RefYear>2024</RefYear> <RefBookTitle>Core Elements of Antibiotic Stewardship</RefBookTitle> <RefPage></RefPage> <RefTotal>Centers for Disease Control and Prevention. Core Elements of Antibiotic Stewardship. 2024. Available from: https://www.cdc.gov/antibiotic-use/hcp/core-elements/index.html</RefTotal> <RefLink>https://www.cdc.gov/antibiotic-use/hcp/core-elements/index.html</RefLink> </Reference> <Reference refNo="54"> <RefAuthor>CDC</RefAuthor> <RefTitle></RefTitle> <RefYear>2024</RefYear> <RefBookTitle>Core Elements of Hospital Antibiotic Stewardship Programs</RefBookTitle> <RefPage></RefPage> <RefTotal>CDC. Core Elements of Hospital Antibiotic Stewardship Programs. 2024. Available from: https://www.cdc.gov/antibiotic-use/hcp/core-elements/hospital.html</RefTotal> <RefLink>https://www.cdc.gov/antibiotic-use/hcp/core-elements/hospital.html</RefLink> </Reference> <Reference refNo="55"> <RefAuthor>Kramer A</RefAuthor> <RefTitle>Role of disinfection in the Infection Prevention Multibarrier System</RefTitle> <RefYear>2007</RefYear> <RefJournal>GMS Krankenhhyg Interdiszip</RefJournal> <RefPage>Doc13</RefPage> <RefTotal>Kramer A. Role of disinfection in the Infection Prevention Multibarrier System. GMS Krankenhhyg Interdiszip. 2007 Sep;2(1):Doc13.</RefTotal> </Reference> <Reference refNo="56"> <RefAuthor>Commission for Hospital Hygiene and Infection Prevention (KRINKO)</RefAuthor> <RefTitle>Hygiene requirements for cleaning and disinfection of surfaces: recommendation of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute</RefTitle> <RefYear>2024</RefYear> <RefJournal>GMS Hyg Infect Control</RefJournal> <RefPage>Doc13</RefPage> <RefTotal>Commission for Hospital Hygiene and Infection Prevention (KRINKO). Hygiene requirements for cleaning and disinfection of surfaces: recommendation of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute. GMS Hyg Infect Control. 2024 Mar 5;19:Doc13. DOI: 10.3205/dgkh000468</RefTotal> <RefLink>https://doi.org/10.3205/dgkh000468</RefLink> </Reference> <Reference refNo="57"> <RefAuthor>Puro V</RefAuthor> <RefAuthor>Coppola N</RefAuthor> <RefAuthor>Frasca A</RefAuthor> <RefAuthor>Gentile I</RefAuthor> <RefAuthor>Luzzaro F</RefAuthor> <RefAuthor>Peghetti A</RefAuthor> <RefAuthor>Sganga G</RefAuthor> <RefTitle>Pillars for prevention and control of healthcare-associated infections: an Italian expert opinion statement</RefTitle> <RefYear>2022</RefYear> <RefJournal>Antimicrob Resist Infect Control</RefJournal> <RefPage>87</RefPage> <RefTotal>Puro V, Coppola N, Frasca A, Gentile I, Luzzaro F, Peghetti A, Sganga G. Pillars for prevention and control of healthcare-associated infections: an Italian expert opinion statement. Antimicrob Resist Infect Control. 2022 Jun;11(1):87. DOI: 10.1186/s13756-022-01125-8</RefTotal> <RefLink>https://doi.org/10.1186/s13756-022-01125-8</RefLink> </Reference> <Reference refNo="58"> <RefAuthor>Koo E</RefAuthor> <RefAuthor>McNamara S</RefAuthor> <RefAuthor>Lansing B</RefAuthor> <RefAuthor>Olmsted RN</RefAuthor> <RefAuthor>Rye RA</RefAuthor> <RefAuthor>Fitzgerald T</RefAuthor> <RefAuthor>Mody L</RefAuthor> <RefAuthor> Targeted Infection Prevention (TIP) Study Team</RefAuthor> <RefAuthor>Ann Arbor</RefAuthor> <RefAuthor>Michigan</RefAuthor> <RefTitle>Making infection prevention education interactive can enhance knowledge and improve outcomes: Results from the Targeted Infection Prevention (TIP) Study</RefTitle> <RefYear>2016</RefYear> <RefJournal>Am J Infect Control</RefJournal> <RefPage>1241-6</RefPage> <RefTotal>Koo E, McNamara S, Lansing B, Olmsted RN, Rye RA, Fitzgerald T, Mody L; Targeted Infection Prevention (TIP) Study Team, Ann Arbor, Michigan. Making infection prevention education interactive can enhance knowledge and improve outcomes: Results from the Targeted Infection Prevention (TIP) Study. Am J Infect Control. 2016 Nov;44(11):1241-6. DOI: 10.1016/j.ajic.2016.03.016</RefTotal> <RefLink>https://doi.org/10.1016/j.ajic.2016.03.016</RefLink> </Reference> <Reference refNo="59"> <RefAuthor>Boyce JM</RefAuthor> <RefAuthor>Laughman JA</RefAuthor> <RefAuthor>Ader MH</RefAuthor> <RefAuthor>Wagner PT</RefAuthor> <RefAuthor>Parker AE</RefAuthor> <RefAuthor>Arbogast JW</RefAuthor> <RefTitle>Impact of an automated hand hygiene monitoring system and additional promotional activities on hand hygiene performance rates and healthcare-associated infections</RefTitle> <RefYear>2019</RefYear> <RefJournal>Infect Control Hosp Epidemiol</RefJournal> <RefPage>741-7</RefPage> <RefTotal>Boyce JM, Laughman JA, Ader MH, Wagner PT, Parker AE, Arbogast JW. Impact of an automated hand hygiene monitoring system and additional promotional activities on hand hygiene performance rates and healthcare-associated infections. Infect Control Hosp Epidemiol. 2019 Jul;40(7):741-7. DOI: 10.1017/ice.2019.77</RefTotal> <RefLink>https://doi.org/10.1017/ice.2019.77</RefLink> </Reference> <Reference refNo="60"> <RefAuthor>Zwicker P</RefAuthor> <RefAuthor>Meng M</RefAuthor> <RefAuthor>Friesecke S</RefAuthor> <RefAuthor>Stein T</RefAuthor> <RefAuthor>Herzog A</RefAuthor> <RefAuthor>Herzer C</RefAuthor> <RefAuthor>Kammerlander M</RefAuthor> <RefAuthor>Gebhardt T</RefAuthor> <RefAuthor>Kugler C</RefAuthor> <RefAuthor>Kramer A</RefAuthor> <RefTitle>An interactive feedback system for increasing hand antisepsis adherence in stationary intensive care</RefTitle> <RefYear>2023</RefYear> <RefJournal>J Hosp Infect</RefJournal> <RefPage>73-80</RefPage> <RefTotal>Zwicker P, Meng M, Friesecke S, Stein T, Herzog A, Herzer C, Kammerlander M, Gebhardt T, Kugler C, Kramer A. An interactive feedback system for increasing hand antisepsis adherence in stationary intensive care. J Hosp Infect. 2023 Mar;133:73-80. DOI: 10.1016/j.jhin.2022.12.017</RefTotal> <RefLink>https://doi.org/10.1016/j.jhin.2022.12.017</RefLink> </Reference> <Reference refNo="61"> <RefAuthor>Garcia R</RefAuthor> <RefAuthor>Barnes S</RefAuthor> <RefAuthor>Boukidjian R</RefAuthor> <RefAuthor>Goss LK</RefAuthor> <RefAuthor>Spencer M</RefAuthor> <RefAuthor>Septimus EJ</RefAuthor> <RefAuthor>Wright MO</RefAuthor> <RefAuthor>Munro S</RefAuthor> <RefAuthor>Reese SM</RefAuthor> <RefAuthor>Fakih MG</RefAuthor> <RefAuthor>Edmiston CE</RefAuthor> <RefAuthor>Levesque M</RefAuthor> <RefTitle>Recommendations for change in infection prevention programs and practice</RefTitle> <RefYear>2022</RefYear> <RefJournal>Am J Infect Control</RefJournal> <RefPage>1281-95</RefPage> <RefTotal>Garcia R, Barnes S, Boukidjian R, Goss LK, Spencer M, Septimus EJ, Wright MO, Munro S, Reese SM, Fakih MG, Edmiston CE, Levesque M. Recommendations for change in infection prevention programs and practice. Am J Infect Control. 2022 Dec;50(12):1281-95. DOI: 10.1016/j.ajic.2022.04.007</RefTotal> <RefLink>https://doi.org/10.1016/j.ajic.2022.04.007</RefLink> </Reference> <Reference refNo="62"> <RefAuthor>Livingston SH</RefAuthor> <RefAuthor>Cadnum JL</RefAuthor> <RefAuthor>Benner KJ</RefAuthor> <RefAuthor>Donskey CJ</RefAuthor> <RefTitle>Efficacy of an ultraviolet-A lighting system for continuous decontamination of health care-associated pathogens on surfaces</RefTitle> <RefYear>2020</RefYear> <RefJournal>Am J Infect Control</RefJournal> <RefPage>337-9</RefPage> <RefTotal>Livingston SH, Cadnum JL, Benner KJ, Donskey CJ. Efficacy of an ultraviolet-A lighting system for continuous decontamination of health care-associated pathogens on surfaces. Am J Infect Control. 2020 Mar;48(3):337-9. DOI: 10.1016/j.ajic.2019.08.003</RefTotal> <RefLink>https://doi.org/10.1016/j.ajic.2019.08.003</RefLink> </Reference> <Reference refNo="63"> <RefAuthor>Anderson DJ</RefAuthor> <RefAuthor>Gergen MF</RefAuthor> <RefAuthor>Smathers E</RefAuthor> <RefAuthor>Sexton DJ</RefAuthor> <RefAuthor>Chen LF</RefAuthor> <RefAuthor>Weber DJ</RefAuthor> <RefAuthor>Rutala WA</RefAuthor> <RefTitle>Decontamination of targeted pathogens from patient rooms using an automated ultraviolet-C-emitting device</RefTitle> <RefYear>2013</RefYear> <RefJournal>Infect Control Hosp Epidemiol</RefJournal> <RefPage>466-71</RefPage> <RefTotal>Anderson DJ, Gergen MF, Smathers E, Sexton DJ, Chen LF, Weber DJ, Rutala WA. Decontamination of targeted pathogens from patient rooms using an automated ultraviolet-C-emitting device. Infect Control Hosp Epidemiol. 2013 May;34(5):466-71. DOI: 10.1086/670215</RefTotal> <RefLink>https://doi.org/10.1086/670215</RefLink> </Reference> <Reference refNo="64"> <RefAuthor>Yang JH</RefAuthor> <RefAuthor>Wu UI</RefAuthor> <RefAuthor>Tai HM</RefAuthor> <RefAuthor>Sheng WH</RefAuthor> <RefTitle>Effectiveness of an ultraviolet-C disinfection system for reduction of healthcare-associated pathogens</RefTitle> <RefYear>2019</RefYear> <RefJournal>J Microbiol Immunol Infect</RefJournal> <RefPage>487-93</RefPage> <RefTotal>Yang JH, Wu UI, Tai HM, Sheng WH. Effectiveness of an ultraviolet-C disinfection system for reduction of healthcare-associated pathogens. J Microbiol Immunol Infect. 2019 Jun;52(3):487-93. DOI: 10.1016/j.jmii.2017.08.017</RefTotal> <RefLink>https://doi.org/10.1016/j.jmii.2017.08.017</RefLink> </Reference> <Reference refNo="65"> <RefAuthor>Elgujja AA</RefAuthor> <RefAuthor>Altalhi HH</RefAuthor> <RefAuthor>Ezreqat S</RefAuthor> <RefTitle>Review of the efficacy of ultraviolet C for surface decontamination</RefTitle> <RefYear>2020</RefYear> <RefJournal>J Nat Sci Med</RefJournal> <RefPage>8-12</RefPage> <RefTotal>Elgujja AA, Altalhi HH, Ezreqat S. Review of the efficacy of ultraviolet C for surface decontamination. J Nat Sci Med. 2020 Jan-Mar; 3(1): 8-12. DOI: 10.4103/JNSM.JNSM_21_19</RefTotal> <RefLink>https://doi.org/10.4103/JNSM.JNSM_21_19</RefLink> </Reference> <Reference refNo="66"> <RefAuthor>Ng MK</RefAuthor> <RefAuthor>Mont MA</RefAuthor> <RefAuthor>Bonutti PM</RefAuthor> <RefTitle>UVCeed: Leveraging augmented reality, artificial intelligence, and gamification for enhanced ultraviolet C disinfection</RefTitle> <RefYear>2025</RefYear> <RefJournal>Cureus</RefJournal> <RefPage>e80240</RefPage> <RefTotal>Ng MK, Mont MA, Bonutti PM. UVCeed: Leveraging augmented reality, artificial intelligence, and gamification for enhanced ultraviolet C disinfection. Cureus. 2025 Mar 8;17(3):e80240. DOI: 10.7759/cureus.80240</RefTotal> <RefLink>https://doi.org/10.7759/cureus.80240</RefLink> </Reference> <Reference refNo="67"> <RefAuthor>CS Medical</RefAuthor> <RefTitle></RefTitle> <RefYear>2025</RefYear> <RefBookTitle>Resources Gallery</RefBookTitle> <RefPage></RefPage> <RefTotal>CS Medical. Resources Gallery. 2025. Available from: https://csmedicalllc.com/resources-gallery?submissionGuid=97ef27aa-5aed-492f-9693-f932998ca4e1</RefTotal> <RefLink>https://csmedicalllc.com/resources-gallery?submissionGuid=97ef27aa-5aed-492f-9693-f932998ca4e1</RefLink> </Reference> <Reference refNo="68"> <RefAuthor>U.S. Food & Drug Administration</RefAuthor> <RefTitle></RefTitle> <RefYear>2021</RefYear> <RefBookTitle>Information about Automated Endoscope Reprocessors (AERs) and FDA's Evaluation</RefBookTitle> <RefPage></RefPage> <RefTotal>U.S. Food & Drug Administration. Information about Automated Endoscope Reprocessors (AERs) and FDA's Evaluation. 2021. Available from: https://www.fda.gov/medical-devices/reprocessing-reusable-medical-devices/information-about-automated-endoscope-reprocessors-aers-and-fdas-evaluation</RefTotal> <RefLink>https://www.fda.gov/medical-devices/reprocessing-reusable-medical-devices/information-about-automated-endoscope-reprocessors-aers-and-fdas-evaluation</RefLink> </Reference> <Reference refNo="69"> <RefAuthor>Godbole AA</RefAuthor> <RefAuthor>Paras</RefAuthor> <RefAuthor>Mehra M</RefAuthor> <RefAuthor>Banerjee S</RefAuthor> <RefAuthor>Roy P</RefAuthor> <RefAuthor>Deb N</RefAuthor> <RefAuthor>Jagtap S</RefAuthor> <RefTitle>Enhancing Infection Control in ICUS Through AI: A Literature Review</RefTitle> <RefYear>2025</RefYear> <RefJournal>Health Sci Rep</RefJournal> <RefPage>e70288</RefPage> <RefTotal>Godbole AA, Paras, Mehra M, Banerjee S, Roy P, Deb N, Jagtap S. Enhancing Infection Control in ICUS Through AI: A Literature Review. Health Sci Rep. 2025 Jan;8(1):e70288. DOI: 10.1002/hsr2.70288</RefTotal> <RefLink>https://doi.org/10.1002/hsr2.70288</RefLink> </Reference> <Reference refNo="70"> <RefAuthor>Omori K</RefAuthor> <RefAuthor>Shigemoto N</RefAuthor> <RefAuthor>Kitagawa H</RefAuthor> <RefAuthor>Nomura T</RefAuthor> <RefAuthor>Kaiki Y</RefAuthor> <RefAuthor>Miyaji K</RefAuthor> <RefAuthor>Akita T</RefAuthor> <RefAuthor>Kobayashi T</RefAuthor> <RefAuthor>Hattori M</RefAuthor> <RefAuthor>Hasunuma N</RefAuthor> <RefAuthor>Tanaka J</RefAuthor> <RefAuthor>Ohge H</RefAuthor> <RefTitle>Virtual reality as a learning tool for improving infection control procedures</RefTitle> <RefYear>2023</RefYear> <RefJournal>Am J Infect Control</RefJournal> <RefPage>129-34</RefPage> <RefTotal>Omori K, Shigemoto N, Kitagawa H, Nomura T, Kaiki Y, Miyaji K, Akita T, Kobayashi T, Hattori M, Hasunuma N, Tanaka J, Ohge H. Virtual reality as a learning tool for improving infection control procedures. Am J Infect Control. 2023 Feb;51(2):129-34. DOI: 10.1016/j.ajic.2022.05.023</RefTotal> <RefLink>https://doi.org/10.1016/j.ajic.2022.05.023</RefLink> </Reference> </References> <Media> <Tables> <Table format="png"> <MediaNo>1</MediaNo> <MediaID>1</MediaID> <Caption><Pgraph><Mark1>Table 1: Prevalence of pathogens in healthcare-associated infections across different regions</Mark1></Pgraph></Caption> </Table> <NoOfTables>1</NoOfTables> </Tables> <Figures> <NoOfPictures>0</NoOfPictures> </Figures> <InlineFigures> <NoOfPictures>0</NoOfPictures> </InlineFigures> <Attachments> <NoOfAttachments>0</NoOfAttachments> </Attachments> </Media> </OrigData> </GmsArticle>